Literature DB >> 2425046

Antigenic structure of polioviruses of serotypes 1, 2 and 3.

P D Minor, M Ferguson, D M Evans, J W Almond, J P Icenogle.   

Abstract

The antigenic sites recognized by monoclonal antibodies with neutralizing activity for the Sabin vaccine strains of poliovirus of serotypes 1, 2 and 3 have been studied by the isolation and characterization of mutants resistant to neutralization by antibody. Three distinct sites have been identified which are designated site 1, site 2 and site 3. Site 1 includes a region of 12 amino acids of VP1, from residues 89 to 100, and a corresponding region of VP1 has been identified as an antigenic site for poliovirus 2. This site was strongly immunodominant in type 2 and type 3 but was not detected for poliovirus 1. Site 2 is a complex site including residues 220 to 222 from VP1 (site 2a) with residues including 169 and 170 and others of VP2 (site 2b). Both site 2a and site 2b have been detected in type 1 poliovirus, while as yet only site 2b has been detected in type 3 poliovirus. Site 3 is a complex site including residues 286 to 290 from VP1 (site 3a) with residues including 58 and 59 and others of VP3 (site 3b). Both sites 3a and 3b have been detected in type 3 poliovirus, while as yet only site 3b has been detected in type 1 poliovirus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425046     DOI: 10.1099/0022-1317-67-7-1283

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  100 in total

1.  Multicenter quality assessment of PCR methods for detection of enteroviruses.

Authors:  P Muir; A Ras; P E Klapper; G M Cleator; K Korn; C Aepinus; A Fomsgaard; P Palmer; A Samuelsson; A Tenorio; B Weissbrich; A M van Loon
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

2.  Combined cell culture enzyme-linked immunosorbent assay for quantification of poliovirus neutralization- relevant antibodies.

Authors:  A F Wahby
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

3.  Molecular basis of antigenic structures of poliovirus: implications for their evolution during morphogenesis.

Authors:  K Wiegers; R Dernick
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

4.  Postinfection treatment with antiviral serum results in survival of neural cells productively infected with virulent poliovirus.

Authors:  E A Tolskaya; T A Ivannikova; M S Kolesnikova; S G Drozdov; V I Agol
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

Review 5.  Poliomyelitis: eradication in sight.

Authors:  J L Melnick
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

6.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

7.  Widespread circulation of echovirus type 13 demonstrated by increased seroprevalence in Toyama, Japan, between 2000 and 2003.

Authors:  Masae Iwai; Hiromu Yoshida; Mayumi Obara; Eiji Horimoto; Kazuya Nakamura; Takenori Takizawa; Takeshi Kurata; Mineyuki Mizuguchi; Tohru Daikoku; Kimiyasu Shiraki
Journal:  Clin Vaccine Immunol       Date:  2010-03-24

8.  Genomic analysis of two novel human enterovirus C genotypes found in respiratory samples from Peru.

Authors:  Rafal Tokarz; David L Hirschberg; Stephen Sameroff; Saddef Haq; Giannina Luna; Andrew J Bennett; Maria Silva; Mariana Leguia; Matthew Kasper; Daniel G Bausch; W Ian Lipkin
Journal:  J Gen Virol       Date:  2012-10-03       Impact factor: 3.891

9.  Characterization of a simian hepatitis A virus (HAV): antigenic and genetic comparison with human HAV.

Authors:  E A Brown; R W Jansen; S M Lemon
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  Molecular pathogenesis of type 2 poliovirus in mice.

Authors:  T Couderc; B Guinguene; F Horaud; A Aubert-Combiescu; R Crainic
Journal:  Eur J Epidemiol       Date:  1989-09       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.